The drug eluting stents market globally was USD 7.21 Billion in 2022. It is projected to reach USD 12.18 Billion by 2032, with a revenue growth rate of 6% during the forecast period. One of the primary drivers of revenue growth in the drug eluting stent market is the increasing incidence of cardiovascular disorders, including coronary artery disease and peripheral artery disease. These conditions pose a significant health burden globally, with approximately 18 million deaths attributed to cardiovascular illnesses each year, making them the leading cause of mortality worldwide. Factors such as an aging population and sedentary lifestyle have further contributed to the increased risk of developing cardiovascular diseases, thereby raising the demand for drug eluting stents.
Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/1786
Major Companies and Competitive Landscape:
Some of the major companies included in the global drug eluting stent market are:
- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic
- Cordis Corporation (a Johnson & Johnson company)
- Terumo Corporation
- Biosensors International Group, Ltd.
- Biotronik SE & Co. KG
- St. Jude Medical, Inc.
To know more about the report @ https://www.reportsanddata.com/report-detail/drug-eluting-stent-market
The driving factors of the Drug Eluting Stent Market include:
- Increasing incidence of cardiovascular disorders: The rising prevalence of cardiovascular diseases, such as coronary artery disease and peripheral artery disease, is a major driver for the demand of drug eluting stents. These stents are used in the treatment of blocked or narrowed arteries, providing a minimally invasive solution.
- Growing preference for minimally invasive procedures: There is a growing trend towards minimally invasive procedures in healthcare. Drug eluting stents offer a less invasive alternative to traditional surgical interventions, resulting in shorter hospital stays, reduced recovery time, and improved patient outcomes. This preference for minimally invasive procedures contributes to the market growth.
- Advancements in stent technology: Continuous advancements in stent technology have led to the development of innovative drug eluting stents with improved efficacy and safety profiles. These advancements, including the use of biodegradable polymers and drug coatings, have expanded the application and acceptance of drug eluting stents, driving market growth.
- Aging population and lifestyle factors: The aging population and the adoption of sedentary lifestyles have contributed to the increased prevalence of cardiovascular diseases. As a result, there is a higher demand for interventions such as drug eluting stents to address the growing cardiovascular health concerns among this demographic.
On the other hand, there are a few restraints that can impact the Drug Eluting Stent Market:
- High cost: Drug eluting stents can be expensive compared to bare metal stents, which can limit their affordability and accessibility, particularly in regions with limited healthcare resources or in low-income populations.
- Safety concerns: Although drug eluting stents have proven efficacy, there have been concerns regarding potential long-term risks associated with their use, such as late stent thrombosis and in-stent restenosis. These safety concerns may impact market growth and influence the choice of alternative treatment options.
- Availability of alternative treatments: There are alternative treatment options available for cardiovascular diseases, including medication therapy and bypass surgeries. The availability of these alternatives may impact the demand for drug eluting stents and pose a restraint on the market growth.
- Regulatory approvals and reimbursement policies: The regulatory approval process for new drug eluting stents can be rigorous and time-consuming, which can delay their entry into the market. Additionally, reimbursement policies and coverage for drug eluting stents may vary across different regions, affecting their adoption and market growth.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1786
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Contact Us:
John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Reports and Data | Web: www.reportsanddata.com
Check our upcoming research reports @ https://www.reportsanddata.com/upcoming-reports
Visit our blog for more industry updates @ https://www.reportsanddata.com/blogs
Browse More Reports:
